Clinical Value and Standardized Use of IL-17 Pathway Antibodies in Chronic Inflammatory Diseases

Basic Mechanisms of the IL-17 Pathway

The IL-17 family is a group of cytokines involved in the regulation of innate and adaptive immunity, among which IL-17A plays a key role in autoimmune and chronic inflammatory responses. IL-17 pathway antibodies specifically bind to IL-17A or block its receptor, thereby affecting downstream inflammatory signaling and reducing the release of related inflammatory factors. This mechanism has been used in the treatment of a variety of diseases characterized by abnormal IL-17 expression, including moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Common Clinical Application Areas

In dermatology and rheumatology/immunology, IL-17 pathway antibodies are generally used in patients who have had an inadequate response to or are intolerant of conventional systemic therapy. Taking psoriasis as an example, clinical practice often considers individuals with concomitant joint involvement, nail damage, or severely affected quality of life. For ankylosing spondylitis, if the efficacy of NSAIDs is limited, some patients may choose IL-17 pathway antibodies as subsequent treatment. It should be noted that different formulations differ in indications, route of administration, and dosing intervals, and they must be used strictly in accordance with product labeling and guideline recommendations.

Standardized Medication Use and Safety Monitoring

IL-17 pathway antibodies are generally tolerable overall, but may increase the risk of superficial fungal infections and inflammatory bowel disease. Screening for infections such as tuberculosis and hepatitis B should be performed before treatment; during treatment, attention should be paid to new-onset diarrhea, abdominal pain, or skin and mucosal infection symptoms. For patients with active inflammatory bowel disease, use is generally not recommended. In addition, women of childbearing age should consider contraception and pregnancy planning, following individualized assessment by a specialist physician.

Patient Management and Long-Term Follow-Up

A complete record of efficacy and safety should be established for the use of IL-17 pathway antibodies, including lesion area, joint symptoms, laboratory indicators, and quality-of-life scores. During long-term follow-up, disease changes and drug response should be regularly assessed, and arbitrary discontinuation or self-adjustment of dosage is not advocated. For those with suboptimal efficacy, drug exposure, treatment adherence, and disease heterogeneity can be comprehensively analyzed, and the next-step plan should be jointly formulated by a specialist team. Standardized management helps improve the sustainability of treatment and reduce unnecessary waste of resources.

Summary and Outlook

IL-17 pathway antibodies provide a therapeutic option with relatively good targeting for autoimmune and inflammatory diseases, but their rational use depends on understanding the mechanism, identifying the appropriate patient population, and full-course management. In the future, with the accumulation of more real-world data and the development of individualized predictive indicators, the treatment landscape of IL-17 pathway antibodies will be further optimized to serve clinical needs more safely and effectively.